Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint blockade offers survival benefits for some non-small-cell lung cancer (NSCLC) patients.
• Lack of robust biomarkers hinders prediction of response to PD-1 inhibitors.
• Limited understanding of NSCLC tumor immune microenvironment diversity.

Purpose of the Study:

• To comprehensively profile the NSCLC tumor immune microenvironment.
• To integrate immunophenotypic data with clinical, genetic, and molecular characteristics.
• To identify potential biomarkers for immunotherapy response in NSCLC.

Main Methods:

• Performed comprehensive flow cytometric immunoprofiling on 51 NSCLC tumors and immune cells.
• Integrated flow cytometry data with next-generation sequencing, mRNA expression, and PD-L1 IHC.
• Analyzed correlations between immunophenotype, clinical factors, and genetic mutations.

Main Results:

• Identified distinct immunologically "hot" (high CD8+ T cells, PD-1+, TIM-3+) and "cold" (low CD8+ T cells, inhibitory markers) clusters.
• "Hot" cluster associated with T cell trafficking, cytotoxic function, and high PD-L1 expression.
• Observed enrichment of squamous subtype and higher mutation burden in the "hot" cluster; no correlation with KRAS/EGFR mutations or smoking history.

Conclusions:

• Immune-based metrics can aid in studying immunotherapy response and resistance in lung cancer.
• Distinct immune microenvironments in NSCLC may influence treatment outcomes.
• Further research into immune profiling could refine personalized immunotherapy strategies.